Is there a case for DHEA replacement?

T. B. Nippoldt, K Sreekumaran Nair

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

There are many hormonal changes that occur with ageing in humans, of which the most dramatic and intriguing change occurs for the adrenal androgenic steroid dehydroepiandosterone (DHEA). There are tantalizing epidemiological data demonstrating a significant association between the changes in circulating DHEA level and changes in the incidence of malignancy, atherosclerosis, Alzheimer's disease and other age-related changes. The pharmacological effects in animals such as rodents and rabbits have demonstrated many beneficial effects, for example increased immune function, the prevention of atherosclerosis, cancer, diabetes and obesity, and the improvement of memory. Clinical studies carried out in small groups of subjects have clearly demonstrated that the administration of DHEA to the elderly increases many hormone levels, including that of insulin-like growth factor-1, (free and total) testosterone, dihydrotestosterone, oestrone and oestradiol. It remains to be clearly defined whether these changes are clinically beneficial, and there is only insufficient information on the side-effects on long-term use. Results from short-term intervention studies in small groups of subjects have not demonstrated any convincing beneficial effects so far. A judgement on whether DHEA replacement has a place in preventing age-related disabilities could be determined only on the basis of results from studies of long-term DHEA replacement in elderly people.

Original languageEnglish (US)
Pages (from-to)507-520
Number of pages14
JournalBailliere's Clinical Endocrinology and Metabolism
Volume12
Issue number3
StatePublished - 1998

Fingerprint

Estrone
Dihydrotestosterone
Somatomedins
Medical problems
Testosterone
Estradiol
Atherosclerosis
Animals
Aging of materials
Steroids
Hormones
Data storage equipment
Rodentia
Neoplasms
Alzheimer Disease
Obesity
Pharmacology
Rabbits
Incidence
Clinical Studies

Keywords

  • Ageing
  • DHEA
  • DHEA-S
  • Sarcopenia

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Is there a case for DHEA replacement? / Nippoldt, T. B.; Nair, K Sreekumaran.

In: Bailliere's Clinical Endocrinology and Metabolism, Vol. 12, No. 3, 1998, p. 507-520.

Research output: Contribution to journalArticle

@article{a9f344339845486d80056f2db25948b3,
title = "Is there a case for DHEA replacement?",
abstract = "There are many hormonal changes that occur with ageing in humans, of which the most dramatic and intriguing change occurs for the adrenal androgenic steroid dehydroepiandosterone (DHEA). There are tantalizing epidemiological data demonstrating a significant association between the changes in circulating DHEA level and changes in the incidence of malignancy, atherosclerosis, Alzheimer's disease and other age-related changes. The pharmacological effects in animals such as rodents and rabbits have demonstrated many beneficial effects, for example increased immune function, the prevention of atherosclerosis, cancer, diabetes and obesity, and the improvement of memory. Clinical studies carried out in small groups of subjects have clearly demonstrated that the administration of DHEA to the elderly increases many hormone levels, including that of insulin-like growth factor-1, (free and total) testosterone, dihydrotestosterone, oestrone and oestradiol. It remains to be clearly defined whether these changes are clinically beneficial, and there is only insufficient information on the side-effects on long-term use. Results from short-term intervention studies in small groups of subjects have not demonstrated any convincing beneficial effects so far. A judgement on whether DHEA replacement has a place in preventing age-related disabilities could be determined only on the basis of results from studies of long-term DHEA replacement in elderly people.",
keywords = "Ageing, DHEA, DHEA-S, Sarcopenia",
author = "Nippoldt, {T. B.} and Nair, {K Sreekumaran}",
year = "1998",
language = "English (US)",
volume = "12",
pages = "507--520",
journal = "Bailliere's Clinical Endocrinology and Metabolism",
issn = "0950-351X",
publisher = "Bailliere Tindall Ltd",
number = "3",

}

TY - JOUR

T1 - Is there a case for DHEA replacement?

AU - Nippoldt, T. B.

AU - Nair, K Sreekumaran

PY - 1998

Y1 - 1998

N2 - There are many hormonal changes that occur with ageing in humans, of which the most dramatic and intriguing change occurs for the adrenal androgenic steroid dehydroepiandosterone (DHEA). There are tantalizing epidemiological data demonstrating a significant association between the changes in circulating DHEA level and changes in the incidence of malignancy, atherosclerosis, Alzheimer's disease and other age-related changes. The pharmacological effects in animals such as rodents and rabbits have demonstrated many beneficial effects, for example increased immune function, the prevention of atherosclerosis, cancer, diabetes and obesity, and the improvement of memory. Clinical studies carried out in small groups of subjects have clearly demonstrated that the administration of DHEA to the elderly increases many hormone levels, including that of insulin-like growth factor-1, (free and total) testosterone, dihydrotestosterone, oestrone and oestradiol. It remains to be clearly defined whether these changes are clinically beneficial, and there is only insufficient information on the side-effects on long-term use. Results from short-term intervention studies in small groups of subjects have not demonstrated any convincing beneficial effects so far. A judgement on whether DHEA replacement has a place in preventing age-related disabilities could be determined only on the basis of results from studies of long-term DHEA replacement in elderly people.

AB - There are many hormonal changes that occur with ageing in humans, of which the most dramatic and intriguing change occurs for the adrenal androgenic steroid dehydroepiandosterone (DHEA). There are tantalizing epidemiological data demonstrating a significant association between the changes in circulating DHEA level and changes in the incidence of malignancy, atherosclerosis, Alzheimer's disease and other age-related changes. The pharmacological effects in animals such as rodents and rabbits have demonstrated many beneficial effects, for example increased immune function, the prevention of atherosclerosis, cancer, diabetes and obesity, and the improvement of memory. Clinical studies carried out in small groups of subjects have clearly demonstrated that the administration of DHEA to the elderly increases many hormone levels, including that of insulin-like growth factor-1, (free and total) testosterone, dihydrotestosterone, oestrone and oestradiol. It remains to be clearly defined whether these changes are clinically beneficial, and there is only insufficient information on the side-effects on long-term use. Results from short-term intervention studies in small groups of subjects have not demonstrated any convincing beneficial effects so far. A judgement on whether DHEA replacement has a place in preventing age-related disabilities could be determined only on the basis of results from studies of long-term DHEA replacement in elderly people.

KW - Ageing

KW - DHEA

KW - DHEA-S

KW - Sarcopenia

UR - http://www.scopus.com/inward/record.url?scp=0032454161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032454161&partnerID=8YFLogxK

M3 - Article

C2 - 10332570

AN - SCOPUS:0032454161

VL - 12

SP - 507

EP - 520

JO - Bailliere's Clinical Endocrinology and Metabolism

JF - Bailliere's Clinical Endocrinology and Metabolism

SN - 0950-351X

IS - 3

ER -